Literature DB >> 28932710

2-Drug regimens in HIV treatment: pharmacological considerations.

David Back.   

Abstract

Year:  2017        PMID： 28932710      PMCID： PMC5601093          DOI： 10.18683/germs.2017.1115

Source DB:  PubMed          Journal:  Germs        ISSN： 2248-2997


× No keyword cloud information.
  3 in total

Review 1.  Candidates for inclusion in a universal antiretroviral regimen: dolutegravir.

Authors:  Pedro Cahn
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

2.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321

3.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Authors:  Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177
  3 in total
  7 in total

Review 1.  Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2018-11       Impact factor: 11.431

2.  Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.

Authors:  Jean van Wyk; Mounir Ait-Khaled; Jesus Santos; Stefan Scholten; Michael Wohlfeiler; Faïza Ajana; Bryn Jones; Maria-Claudia Nascimento; Allan R Tenorio; Don E Smith; Jonathan Wright; Brian Wynne
Journal:  J Acquir Immune Defic Syndr       Date:  2021-06-01       Impact factor: 3.771

3.  Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review.

Authors:  Josep M Llibre; Pedro E Cahn; Janet Lo; Tristan J Barber; Cristina Mussini; Berend J van Welzen; Beatriz Hernandez; Cynthia Donovan; Michelle Kisare; Myooran Sithamparanathan; Jean van Wyk
Journal:  Open Forum Infect Dis       Date:  2022-02-10       Impact factor: 3.835

4.  Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.

Authors:  Pedro Cahn; Juan Sierra Madero; José R Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Y Man; Rimgaile Urbaityte; Daisy J Brandon; Mark Underwood; Keith A Pappa; Lloyd Curtis; Kimberly Y Smith; Martin Gartland; Michael Aboud; Jean van Wyk; Brian Wynne
Journal:  AIDS       Date:  2022-01-01       Impact factor: 4.177

5.  Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.

Authors:  M Keith Rawlings; Emilio Letang; Romina Quercia; Richard Grove; Ralph DeMasi; Sherene Min; Vani Vannappagari; Andrew Zolopa; Jean van Wyk; Kimberly Smith
Journal:  Open Forum Infect Dis       Date:  2022-06-24       Impact factor: 4.423

6.  Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José R Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Y Man; Rimgaile Urbaityte; Daisy J Brandon; Mark Underwood; Allan R Tenorio; Keith A Pappa; Brian Wynne; Martin Gartland; Michael Aboud; Jean van Wyk; Kimberly Y Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2020-03-01       Impact factor: 3.771

7.  Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.

Authors:  Jean van Wyk; Faïza Ajana; Fiona Bisshop; Stéphane De Wit; Olayemi Osiyemi; Joaquín Portilla Sogorb; Jean-Pierre Routy; Christoph Wyen; Mounir Ait-Khaled; Maria Claudia Nascimento; Keith A Pappa; Ruolan Wang; Jonathan Wright; Allan R Tenorio; Brian Wynne; Michael Aboud; Martin J Gartland; Kimberly Y Smith
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.